The Department of Disease Control is preparing to discuss ways to use LAAB to treat covids on November 4 after FDA approves expanded indications. It was initially used in people who were just starting to get sick, the elderly group. have a chronic disease of poor immunity as well as protection Clarify and change the vaccine to LAAB if more is needed.
On 3 November, Dr Thares Krasanairawivong Director General of the Department of Disease Control was interviewed about the progress of using ready immunity (Long-acting Antibody: LAAB) in the treatment that LAAB was originally registered for the first time. Used for injections to prevent COVID-19, but recently when more studies have been done abroad The FDA of Thailand has also approved the expansion of the indications for the treatment of COVID-19, high risk groups or poor immunity . to be distributed in each service unit
